Behind the Breakthroughs

Join host Jonathan D. Grinstein, PhD, North American Editor for Inside Precision Medicine , as he uncovers the stories behind the pioneers driving the precision medicine revolution. Behind the Breakthroughs features candid interviews with seasoned veterans and rising stars, exploring their origin stories and groundbreaking contributions advancing the frontiers of patient diagnosis, treatment, and care. In every episode, Jonathan goes beyond the science, diving deep into the personal and professional journeys of those striving to make these incredible new therapies more equitable and accessible globally. You'll discover how emerging technologies in molecular diagnostics, next-generation sequencing, genetic medicines (e.g., cell and gene therapies), and AI/ML are transforming treatment and bringing precision medicine closer to the forefront of healthcare. Whether you’re a researcher at a large pharma company or small biotech startup, a clinician at a major h

Behind the Breakthroughs is a technology podcast hosted by Inside Precision Medicine, with 51 episodes on record and a Required Pod Score of 80.

Inside Precision Medicine hosts Behind the Breakthroughs, a technology show with 51 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #51

  Wei-Wu He: Craig Venter’s Legacy and the Future of Human Longevity

  Sep 23, 20261h 2m

  Human Longevity executive chairman Wei-Wu He discusses how the integration of genomics, advanced imaging, and artificial intelligence could transform disease prediction and personalized preventive medicine. Reflecting on Craig Venter’s legacy, he explores the challenges of democratizing precision medicine and the quest to extend human healthspan by identifying and intervening in disease before symptoms emerge. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by Erick Ziegler Brought to you by Inside Precision Medicine (SAGE Publishing) Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes
• 

  Episode #50

  Palani Kumaresan: Roche Diagnostics Is Ramping Up—Should Illumina Be Worried?

  Sep 9, 202659 min

  Roche’s AXELIOS sequencer, Alzheimer’s blood test, and push to automate mass spectrometry point to a broader strategy of making advanced diagnostics routine. Whether AXELIOS can meaningfully challenge Illumina’s sequencing dominance, however, remains an open question. Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes
• 

  Episode #49

  Ken Greenberg: Can Ultrasound Shatter the Gene Therapy Delivery Bottleneck?

  Aug 26, 20261 hour

  Gene therapy’s biggest bottleneck remains delivery: getting increasingly sophisticated genetic medicines safely into the right cells. SonoThera is taking a radically different approach, using ultrasound and microbubbles instead of viral vectors and nanoparticles, which could allow for larger payloads, repeat dosing, and precise tissue targeting. The key question is whether this seemingly too-good-to-be-true approach can work in humans after promising results across multiple organs in animals. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by Erick Ziegler Brought to you by Inside Precision Medicine (SAGE Publishing) Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes
• 

  Episode #48

  David Thaisrivongs: Goldilocks and the First Oral PCSK9 Inhibitor

  Aug 12, 202642 min

  Biocatalysis has evolved from a scientific curiosity into a powerful manufacturing platform, culminating in enlicitide, the first oral macrocyclic peptide PCSK9 inhibitor. Merck’s David Thaisrivongs explains how enzyme engineering helped create this “Goldilocks” class of medicines—and could open previously inaccessible drug targets to oral therapies. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by Erick Ziegler Brought to you by Inside Precision Medicine (SAGE Publishing) Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes
• 

  Episode #47

  Beaubrun and Acharya: No Antibiotic Without a Diagnostic

  Jul 29, 202657 min

  Antimicrobial resistance (AMR) isn't going to be solved by new antibiotics alone—it also requires identifying resistant infections quickly enough to guide treatment and prevent transmission. In this episode of Behind the Breakthroughs , Anne Beaubrun, PhD, of Cepheid and Amish Acharya, PhD, of the Fleming Initiative, discuss how rapid molecular diagnostics, including the TRACE-CPE study, could bring precision medicine to infectious disease by enabling earlier detection of carbapenemase-producing Enterobacterales (CPE)—dangerous, last-resort antibiotic-resistant bacteria that are spreading rapidly in hospitals. They also explore the scientific, clinical, and policy challenges of making rapid diagnostics a routine part of healthcare worldwide. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by Erick Ziegler Brought to you by Inside Precision Medicine (SAGE Publishing) Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes

Recent guests on Behind the Breakthroughs. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.